Selection of 5 Posters

The authors of the study conclude that "Early data indicates that the use of EUS-guided implantation of P-32 is highly feasible, well tolerated and has an acceptable safety profile in combination with standard first-line chemotherapy for LAPC. Preliminary data shows evidence of tumour regression and local disease control. These results, however, warrant further evaluation. The clinical trial is ongoing and additional safety and efficacy data will be presented. ClinicalTrials.gov Identifier: NCT03003078. Acknowledgement: Nab-paclitaxel was supported by Specialised Therapeutics Australia Pty Ltd."

 

Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.140, https://doi.org/10.1093/annonc/mdy151.140

 

S Kokkali, et al. POSTER

The authors of the study conclude that "Biweekly combination of gemcitabine and nab-paclitaxel seems to be as safe and efficient as the original regimen. It reduced the patients' discomfort as well as the cost of the treatment."

 

Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.141, https://doi.org/10.1093/annonc/mdy151.141

 

M Sasaki, et al. POSTER

 

The authors of the study conclude that "The safety of GN, in terms of the risk of hematological toxicity was similar between the NB-G and HB-G groups in this study. For APC patients presenting with hyperbilirubinemia secondary to bile duct obstruction, it might be safe to initiate GN without dose reduction if a suitable procedure for biliary drainage is undertaken prior to the initiation of the treatment."

Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.142, https://doi.org/10.1093/annonc/mdy151.142

 

 

M McNultyet al. POSTER

The authors of the study conclude that "This retrospective study showed that retreatment of advanced pancreatic adenocarcinoma patients with gemcitabine plus nab-paclitaxel could be a suitable third-line treatment option. In order to evaluate the actual efficacy of this third-line chemotherapy regimen, phase III trials would need to be conducted to compare gemcitabine plus nab-paclitaxel with other chemotherapeutic agents."

Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.146, https://doi.org/10.1093/annonc/mdy151.146

 

 

I Choet al. POSTER

The authors of the study conclude that "There was no significant difference in the treatment efficacy of both regimens. However, considering the cost and side effects, Gem+nabPTX is more favorable for metastatic pancreatic cancer patients."

Annals of Oncology, Volume 29, Issue suppl_5, 1 June 2018, mdy151.160, https://doi.org/10.1093/annonc/mdy151.160